Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On December 10, 2020, the Supreme Court of Canada dismissed Pfizer's application for leave to appeal (Docket No. 39150) a decision upholding an interlocutory decision...
To print this article, all you need is to be registered or login on Mondaq.com.
On December 10, 2020, the Supreme Court of Canada dismissed
Pfizer's application for leave to appeal (Docket No. 39150) a decision upholding an interlocutory
decision on a question relevant to the assessment of section 8
damages related to pregabalin
(Pfizer's LYRICA). As
previously reported, the Federal Court of Appeal dismissed
Pfizer's appeal from the Federal Court decision holding that
Pfizer's defence of ex turpi causa by reason
of infringement was not legally viable as Pfizer did not bring an
infringement action against Pharmascience in the real world
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
Supreme Court Denies Leave Of Interlocutory Decision In Pregabalin Section 8 Case
CanadaFood, Drugs, Healthcare, Life Sciences
Contributor
Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
